Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 6/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951546 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 | |
| SCHEMBL12620176 | 0.85 | ALDH1A1 (0.58) | SMN1; SMN2KDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL29951633 | 0.85 | KDM4E (0.53) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 | |
| SCHEMBL26768714 | 0.84 | KDM4E (0.63) | SMN1; SMN2KDM4EPOLBALDH1A1MAPT | |
| SCHEMBL29853691 | 0.84 | KDM4E (0.63) | SMN1; SMN2KDM4EPOLBALDH1A1MAPT | |
| SCHEMBL7267474 | 0.82 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 | |
| SCHEMBL29853676 | 0.82 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 | |
| SCHEMBL29952914 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 | |
| SCHEMBL383820 | 0.80 | ALDH1A1 (0.66) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 | |
| Benzene SCHEMBL29227606 | 0.79 | ALDH1A1 (0.63) | SMN1; SMN2KDM4EPOLBAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104140387-B | A kind of preparation method of N-tertbutyloxycarbonyl-azetidine aromatic ether/heteroaromatic ether compound | TETRANOV PHARMACY STOCK INC. (CN) | 2016-11-30 | — | — | CN | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| EP-2817304-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BioChromix NewCo AB (SE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | SMN1; SMN2 41/4885KDM4E 4549/4885POLB 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.